Market Overview

UPDATE: Bank of America Raises PT to $70 on Baxter International; Gambro Strategic Fit at Steep Price

Share:
Related BAX
Earnings Scheduled For July 29, 2015
Baxter Investors Looking For Better Spot; BMO Downgrades Stock
Baxalta publishes encouraging Phase 3 data for its investigational Von Willebrand treatment (Seeking Alpha)

Bank of America reiterated its Buy rating on Baxter International (NYSE: BAX) and increased its price target from $67 to $70.

Bank of America commented, "On Friday the Wall Street Journal and several other media outlets reported that BAX is in talks to acquire privately held Gambro for $4bn (BAX's market cap is $38bn). Gambro is the #2 share player in the hemodialysis technology market where BAX has little presence, and BAX is #1 in the peritoneal dialysis market where Gambro has no presence. In our view, in the hands of BAX, Gambro would be a much tougher HD competitor and a strong strategic fit, with the potential for significant synergies, but a $4bn price tag creates a very high hurdle for positive returns in our view."

Baxter International closed at $67.18 on Friday.

Latest Ratings for BAX

DateFirmActionFromTo
Jul 2015Leerink SwannDowngradesOutperformMarket Perform
Jul 2015Deutsche BankMaintainsHold
Jul 2015BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BAX)

Get Benzinga's Newsletters